Top

Published in:

01-12-2021 | Breast Cancer | Research article

Sublethal doxorubicin promotes migration and invasion of breast cancer cells: role of Src Family non-receptor tyrosine kinases

Authors: Samia Mohammed, Achraf A. Shamseddine, Benjamin Newcomb, Ronald S. Chavez, Tyler D. Panzner, Allen H. Lee, Daniel Canals, Chioma M. Okeoma, Christopher J. Clarke, Yusuf A. Hannun

Published in: Breast Cancer Research | Issue 1/2021

Abstract

Background

Doxorubicin (Dox) is a widely used chemotherapy, but its effectiveness is limited by dose-dependent side effects. Although lower Dox doses reduce this risk, studies have reported higher recurrence of local disease with no improvement in survival rate in patients receiving low doses of Dox. To effectively mitigate this, a better understanding of the adverse effects of suboptimal Dox doses is needed.

Methods

Effects of sublethal dose of Dox on phenotypic changes were assessed with light and confocal microscopy. Migratory and invasive behavior were assessed by wound healing and transwell migration assays. MTT and LDH release assays were used to analyze cell growth and cytotoxicity. Flow cytometry was employed to detect cell surface markers of cancer stem cell population. Expression and activity of matrix metalloproteinases were probed with qRT-PCR and zymogen assay. To identify pathways affected by sublethal dose of Dox, exploratory RNAseq was performed and results were verified by qRT-PCR in multiple cell lines (MCF7, ZR75-1 and U-2OS). Regulation of Src Family kinases (SFK) by key players in DNA damage response was assessed by siRNA knockdown along with western blot and qRT-PCR. Dasatinib and siRNA for Fyn and Yes was employed to inhibit SFKs and verify their role in increased migration and invasion in MCF7 cells treated with sublethal doses of Dox.

Results

The results show that sublethal Dox treatment leads to increased migration and invasion in otherwise non-invasive MCF7 breast cancer cells. Mechanistically, these effects were independent of the epithelial mesenchymal transition, were not due to increased cancer stem cell population, and were not observed with other chemotherapies. Instead, sublethal Dox induces expression of multiple SFK—including Fyn, Yes, and Src—partly in a p53 and ATR-dependent manner. These effects were validated in multiple cell lines. Functionally, inhibiting SFKs with Dasatinib and specific downregulation of Fyn suppressed Dox-induced migration and invasion of MCF7 cells.

Conclusions

Overall, this study demonstrates that sublethal doses of Dox activate a pro-invasive, pro-migration program in cancer cells. Furthermore, by identifying SFKs as key mediators of these effects, our results define a potential therapeutic strategy to mitigate local invasion through co-treatment with Dasatinib.

Available only for authorised users

Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998;339(13):900–5. https://doi.org/10.1056/NEJM199809243391307.CrossRefPubMed

Meredith AM, Dass CR. Increasing role of the cancer chemotherapeutic doxorubicin in cellular metabolism. J Pharm Pharmacol. 2016;68(6):729–41. https://doi.org/10.1111/jphp.12539.CrossRefPubMed

Carmo-Pereira J, Costa FO, Henriques E, Godinho F, Cantinho-Lopes MG, Sales-Luis A, et al. A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma. Br J Cancer. 1987;56(4):471–3. https://doi.org/10.1038/bjc.1987.226.CrossRefPubMedPubMedCentral

Cottin Y, Touzery C, Dalloz F, Coudert B, Toubeau M, Riedinger A, et al. Comparison of epirubicin and doxorubicin cardiotoxicity induced by low doses: evolution of the diastolic and systolic parameters studied by radionuclide angiography. Clin Cardiol. 1998;21(9):665–70. https://doi.org/10.1002/clc.4960210911.CrossRefPubMed

Volkova M, Russell R 3rd. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev. 2011;7(4):214–20.CrossRef

Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med. 1994;330(18):1253–9. https://doi.org/10.1056/NEJM199405053301801.CrossRefPubMed

Taymaz-Nikerel H, Karabekmez ME, Eraslan S, Kirdar B. Doxorubicin induces an extensive transcriptional and metabolic rewiring in yeast cells. Sci Rep. 2018;8(1):13672. https://doi.org/10.1038/s41598-018-31939-9.CrossRefPubMedPubMedCentral

Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics. 2011;21(7):440–6. https://doi.org/10.1097/FPC.0b013e32833ffb56.CrossRefPubMedPubMedCentral

Zhu H, Sarkar S, Scott L, Danelisen I, Trush MA, Jia Z, et al. Doxorubicin redox biology: redox cycling, topoisomerase inhibition, and oxidative stress. React Oxyg Species (Apex). 2016;1(3):189–98. https://doi.org/10.20455/ros.2016.835.CrossRefPubMedPubMedCentral

10.

Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science. 1984;226(4673):466–8. https://doi.org/10.1126/science.6093249.CrossRefPubMed

11.

Qiu Z, Oleinick NL, Zhang J. ATR/CHK1 inhibitors and cancer therapy. Radiother Oncol. 2018;126(3):450–64. https://doi.org/10.1016/j.radonc.2017.09.043.CrossRefPubMed

12.

Awasthi P, Foiani M, Kumar A. ATM and ATR signaling at a glance. J Cell Sci. 2015;128(23):4255–62. https://doi.org/10.1242/jcs.169730.CrossRefPubMed

13.

Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER 3rd, Hurov KE, Luo J, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 2007;316(5828):1160–6. https://doi.org/10.1126/science.1140321.CrossRefPubMed

14.

Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell. 2003;3(5):421–9. https://doi.org/10.1016/S1535-6108(03)00110-7.CrossRefPubMed

15.

Zilfou JT, Lowe SW. Tumor suppressive functions of p53. Cold Spring Harb Perspect Biol. 2009;1(5):a001883. https://doi.org/10.1101/cshperspect.a001883.CrossRefPubMedPubMedCentral

16.

Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer. 2009;9(10):749–58. https://doi.org/10.1038/nrc2723.CrossRefPubMedPubMedCentral

17.

Shamseddine AA, Clarke CJ, Carroll B, Airola MV, Mohammed S, Rella A, et al. P53-dependent upregulation of neutral sphingomyelinase-2: role in doxorubicin-induced growth arrest. Cell Death Dis. 2015;6(10):e1947. https://doi.org/10.1038/cddis.2015.268.CrossRefPubMedPubMedCentral

18.

Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell. 2009;137(3):413–31. https://doi.org/10.1016/j.cell.2009.04.037.CrossRefPubMed

19.

Renu K, GA V, BT P, Arunachalam S. Molecular mechanism of doxorubicin-induced cardiomyopathy - an update. Eur J Pharmacol. 2018;818:241–53.CrossRef

20.

Arai M, Yoguchi A, Takizawa T, Yokoyama T, Kanda T, Kurabayashi M, et al. Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca(2+)-ATPase gene transcription. Circ Res. 2000;86(1):8–14. https://doi.org/10.1161/01.RES.86.1.8.CrossRefPubMed

21.

Abdullah CS, Alam S, Aishwarya R, Miriyala S, Bhuiyan MAN, Panchatcharam M, et al. Doxorubicin-induced cardiomyopathy associated with inhibition of autophagic degradation process and defects in mitochondrial respiration. Sci Rep. 2019;9(1):2002. https://doi.org/10.1038/s41598-018-37862-3.CrossRefPubMedPubMedCentral

22.

Ichikawa Y, Ghanefar M, Bayeva M, Wu R, Khechaduri A, Naga Prasad SV, et al. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Invest. 2014;124(2):617–30. https://doi.org/10.1172/JCI72931.CrossRefPubMedPubMedCentral

23.

Piegari E, De Angelis A, Cappetta D, Russo R, Esposito G, Costantino S, et al. Doxorubicin induces senescence and impairs function of human cardiac progenitor cells. Basic Res Cardiol. 2013;108(2):334. https://doi.org/10.1007/s00395-013-0334-4.CrossRefPubMed

24.

Rodrigues PG, Miranda-Silva D, Costa SM, Barros C, Hamdani N, Moura C, et al. Early myocardial changes induced by doxorubicin in the nonfailing dilated ventricle. Am J Physiol Heart Circ Physiol. 2019;316(3):H459–H75. https://doi.org/10.1152/ajpheart.00401.2018.CrossRefPubMed

25.

Shin HJ, Kwon HK, Lee JH, Gui X, Achek A, Kim JH, et al. Doxorubicin-induced necrosis is mediated by poly-(ADP-ribose) polymerase 1 (PARP1) but is independent of p53. Sci Rep. 2015;5(1):15798. https://doi.org/10.1038/srep15798.CrossRefPubMedPubMedCentral

26.

Du F, Yu L, Wu Y, Wang S, Yao J, Zheng X, et al. miR-137 alleviates doxorubicin resistance in breast cancer through inhibition of epithelial-mesenchymal transition by targeting DUSP4. Cell Death Dis. 2019;10(12):922.CrossRef

27.

Abdullah C, Korkaya H, Iizuka S, Courtneidge SA. SRC increases MYC mRNA expression in estrogen receptor-positive breast cancer via mRNA stabilization and inhibition of p53 Function. Mol Cell Biol. 2018;38(6):e00463–17.CrossRef

28.

Jin X, Wei Y, Liu Y, Lu X, Ding F, Wang J, et al. Resveratrol promotes sensitization to Doxorubicin by inhibiting epithelial-mesenchymal transition and modulating SIRT1/beta-catenin signaling pathway in breast cancer. Cancer Med. 2019;8(3):1246–57. https://doi.org/10.1002/cam4.1993.CrossRefPubMedPubMedCentral

29.

Chen L, Xiao Z, Meng Y, Zhao Y, Han J, Su G, et al. The enhancement of cancer stem cell properties of MCF-7 cells in 3D collagen scaffolds for modeling of cancer and anti-cancer drugs. Biomaterials. 2012;33(5):1437–44. https://doi.org/10.1016/j.biomaterials.2011.10.056.CrossRefPubMed

30.

Martins-Neves SR, Cleton-Jansen AM, Gomes CMF. Therapy-induced enrichment of cancer stem-like cells in solid human tumors: Where do we stand? Pharmacol Res. 2018;137:193–204. https://doi.org/10.1016/j.phrs.2018.10.011.CrossRefPubMed

31.

Guarino M. Src signaling in cancer invasion. J Cell Physiol. 2010;223(1):14–26. https://doi.org/10.1002/jcp.22011.CrossRefPubMed

32.

Parsons SJ, Parsons JT. Src family kinases, key regulators of signal transduction. Oncogene. 2004;23(48):7906–9. https://doi.org/10.1038/sj.onc.1208160.CrossRefPubMed

33.

Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol. 1997;13(1):513–609. https://doi.org/10.1146/annurev.cellbio.13.1.513.CrossRefPubMed

34.

Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer. Oncogene. 2000;19(49):5636–42. https://doi.org/10.1038/sj.onc.1203912.CrossRefPubMed

35.

Yeatman TJ. A renaissance for SRC. Nat Rev Cancer. 2004;4(6):470–80. https://doi.org/10.1038/nrc1366.CrossRefPubMed

36.

Elias D, Ditzel HJ. Fyn is an important molecule in cancer pathogenesis and drug resistance. Pharmacol Res. 2015;100:250–4. https://doi.org/10.1016/j.phrs.2015.08.010.CrossRefPubMed

37.

Jensen AR, David SY, Liao C, Dai J, Keller ET, Al-Ahmadie H, et al. Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells. Clin Cancer Res. 2011;17(10):3112–22. https://doi.org/10.1158/1078-0432.CCR-10-1264.CrossRefPubMedPubMedCentral

38.

Lyu SC, Han DD, Li XL, Ma J, Wu Q, Dong HM, et al. Fyn knockdown inhibits migration and invasion in cholangiocarcinoma through the activated AMPK/mTOR signaling pathway. Oncol Lett. 2018;15(2):2085–90. https://doi.org/10.3892/ol.2017.7542.CrossRefPubMed

39.

Hamamura K, Tsuji M, Hotta H, Ohkawa Y, Takahashi M, Shibuya H, et al. Functional activation of Src family kinase yes protein is essential for the enhanced malignant properties of human melanoma cells expressing ganglioside GD3. J Biol Chem. 2011;286(21):18526–37. https://doi.org/10.1074/jbc.M110.164798.CrossRefPubMedPubMedCentral

40.

Sancier F, Dumont A, Sirvent A, Paquay de Plater L, Edmonds T, David G, et al. Specific oncogenic activity of the Src-family tyrosine kinase c-Yes in colon carcinoma cells. PLoS One. 2011;6(2):e17237.CrossRef

41.

Roseweir AK, Powell A, Horstman SL, Inthagard J, Park JH, McMillan DC, et al. Src family kinases, HCK and FGR, associate with local inflammation and tumour progression in colorectal cancer. Cell Signal. 2019;56:15–22. https://doi.org/10.1016/j.cellsig.2019.01.007.CrossRefPubMed

42.

Yilmaz M, Christofori G. Mechanisms of motility in metastasizing cells. Mol Cancer Res. 2010;8(5):629–42. https://doi.org/10.1158/1541-7786.MCR-10-0139.CrossRefPubMed

43.

Wu X, Yang L, Zheng Z, Li Z, Shi J, Li Y, et al. Src promotes cutaneous wound healing by regulating MMP-2 through the ERK pathway. Int J Mol Med. 2016;37(3):639–48. https://doi.org/10.3892/ijmm.2016.2472.CrossRefPubMedPubMedCentral

44.

Nabeshima K, Inoue T, Shimao Y, Sameshima T. Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol Int. 2002;52(4):255–64. https://doi.org/10.1046/j.1440-1827.2002.01343.x.CrossRefPubMed

45.

Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004;47(27):6658–61. https://doi.org/10.1021/jm049486a.CrossRefPubMed

46.

Steinberg M. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Ther. 2007;29(11):2289–308. https://doi.org/10.1016/j.clinthera.2007.11.005.CrossRefPubMed

47.

Clarke CJ, Mediwala K, Jenkins RW, Sutton CA, Tholanikunnel BG, Hannun YA. Neutral sphingomyelinase-2 mediates growth arrest by retinoic acid through modulation of ribosomal S6 kinase. J Biol Chem. 2011;286(24):21565–76. https://doi.org/10.1074/jbc.M110.193375.CrossRefPubMedPubMedCentral

48.

Canals D, Jenkins RW, Roddy P, Hernandez-Corbacho MJ, Obeid LM, Hannun YA. Differential effects of ceramide and sphingosine 1-phosphate on ERM phosphorylation: probing sphingolipid signaling at the outer plasma membrane. J Biol Chem. 2010;285(42):32476–85. https://doi.org/10.1074/jbc.M110.141028.CrossRefPubMedPubMedCentral

49.

Gandy KA, Canals D, Adada M, Wada M, Roddy P, Snider AJ, et al. Sphingosine 1-phosphate induces filopodia formation through S1PR2 activation of ERM proteins. Biochem J. 2013;449(3):661–72. https://doi.org/10.1042/BJ20120213.CrossRefPubMed

50.

Piccolo SR, Hoffman LM, Conner T, Shrestha G, Cohen AL, Marks JR, et al. Integrative analyses reveal signaling pathways underlying familial breast cancer susceptibility. Mol Syst Biol. 2016;12(3):860. https://doi.org/10.15252/msb.20156506.CrossRefPubMedPubMedCentral

51.

Canals D, Salamone S, Santacreu BJ, Nemeth E, Aguilar D, Hernandez-Corbacho MJ, et al. Ceramide launches an acute anti-adhesion pro-migration cell signaling program in response to chemotherapy. FASEB J. 2020;34(6):7610–30. https://doi.org/10.1096/fj.202000205R.CrossRefPubMed

52.

Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods. 2017;14(4):417–9. https://doi.org/10.1038/nmeth.4197.CrossRefPubMedPubMedCentral

53.

Gupta V, Zhang QJ, Liu YY. Evaluation of anticancer agents using flow cytometry analysis of cancer stem cells. Methods Mol Biol. 2011;716:179–91. https://doi.org/10.1007/978-1-61779-012-6_11.CrossRefPubMedPubMedCentral

54.

Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009;119(6):1429–37. https://doi.org/10.1172/JCI36183.CrossRefPubMedPubMedCentral

55.

Xie YG, Yu Y, Hou LK, Wang X, Zhang B, Cao XC. FYN promotes breast cancer progression through epithelial-mesenchymal transition. Oncol Rep. 2016;36(2):1000–6. https://doi.org/10.3892/or.2016.4894.CrossRefPubMed

56.

McSweeney KM, Bozza WP, Alterovitz WL, Zhang B. Transcriptomic profiling reveals p53 as a key regulator of doxorubicin-induced cardiotoxicity. Cell Death Discov. 2019;5(1):102. https://doi.org/10.1038/s41420-019-0182-6.CrossRefPubMedPubMedCentral

57.

Cheng M, Rizwan A, Jiang L, Bhujwalla ZM, Glunde K. Molecular effects of doxorubicin on choline metabolism in breast cancer. Neoplasia. 2017;19(8):617–27. https://doi.org/10.1016/j.neo.2017.05.004.CrossRefPubMedPubMedCentral

58.

Bandyopadhyay A, Wang L, Agyin J, Tang Y, Lin S, Yeh IT, et al. Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models. PLoS One. 2010;5(4):e10365. https://doi.org/10.1371/journal.pone.0010365.CrossRefPubMedPubMedCentral

59.

Zhong ZF, Tan W, Tian K, Yu H, Qiang WA, Wang YT. Combined effects of furanodiene and doxorubicin on the migration and invasion of MDA-MB-231 breast cancer cells in vitro. Oncol Rep. 2017;37(4):2016–24. https://doi.org/10.3892/or.2017.5435.CrossRefPubMed

60.

Tian ZC, Wang JQ, Ge H. Apatinib ameliorates doxorubicin-induced migration and cancer stemness of osteosarcoma cells by inhibiting Sox2 via STAT3 signalling. J Orthop Translat. 2020;22:132–41. https://doi.org/10.1016/j.jot.2019.07.003.CrossRefPubMed

61.

Comsa S, Cimpean AM, Raica M. The story of MCF-7 breast cancer cell line: 40 years of experience in research. Anticancer Res. 2015;35(6):3147–54.PubMed

62.

Gest C, Joimel U, Huang L, Pritchard LL, Petit A, Dulong C, et al. Rac3 induces a molecular pathway triggering breast cancer cell aggressiveness: differences in MDA-MB-231 and MCF-7 breast cancer cell lines. BMC Cancer. 2013;13(1):63. https://doi.org/10.1186/1471-2407-13-63.CrossRefPubMedPubMedCentral

63.

Liu CL, Chen MJ, Lin JC, Lin CH, Huang WC, Cheng SP, et al. Doxorubicin promotes migration and invasion of breast cancer cells through the upregulation of the RhoA/MLC Pathway. J Breast Cancer. 2019;22(2):185–95. https://doi.org/10.4048/jbc.2019.22.e22.CrossRefPubMedPubMedCentral

64.

Perez-Yepez EA, Ayala-Sumuano JT, Lezama R, Meza I. A novel beta-catenin signaling pathway activated by IL-1beta leads to the onset of epithelial-mesenchymal transition in breast cancer cells. Cancer Lett. 2014;354(1):164–71. https://doi.org/10.1016/j.canlet.2014.08.015.CrossRefPubMed

65.

Liu Y, Du F, Chen W, Yao M, Lv K, Fu P. Knockdown of dual specificity phosphatase 4 enhances the chemosensitivity of MCF-7 and MCF-7/ADR breast cancer cells to doxorubicin. Exp Cell Res. 2013;319(20):3140–9. https://doi.org/10.1016/j.yexcr.2013.08.023.CrossRefPubMed

66.

Ziegler E, Hansen MT, Haase M, Emons G, Grundker C. Generation of MCF-7 cells with aggressive metastatic potential in vitro and in vivo. Breast Cancer Res Treat. 2014;148(2):269–77. https://doi.org/10.1007/s10549-014-3159-4.CrossRefPubMed

67.

Jolly MK, Ware KE, Gilja S, Somarelli JA, Levine H. EMT and MET: necessary or permissive for metastasis? Mol Oncol. 2017;11(7):755–69. https://doi.org/10.1002/1878-0261.12083.CrossRefPubMedPubMedCentral

68.

Steinestel K, Eder S, Schrader AJ, Steinestel J. Clinical significance of epithelial-mesenchymal transition. Clin Transl Med. 2014;3:17.CrossRef

69.

Tan Q, Wang H, Hu Y, Hu M, Li X. Aodengqimuge, et al. Src/STAT3-dependent heme oxygenase-1 induction mediates chemoresistance of breast cancer cells to doxorubicin by promoting autophagy. Cancer Sci. 2015;106(8):1023–32. https://doi.org/10.1111/cas.12712.CrossRefPubMedPubMedCentral

70.

Lee YS, Choi JY, Lee J, Shim DM, Kim J, Park WY, et al. TP53-dependence on the effect of doxorubicin and Src inhibitor combination therapy. Tumour Biol. 2018;40(8):1010428318794217. https://doi.org/10.1177/1010428318794217.CrossRefPubMed

71.

Kudoh K, Ramanna M, Ravatn R, Elkahloun AG, Bittner ML, Meltzer PS, et al. Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res. 2000;60(15):4161–6.PubMed

72.

Vijay V, Moland CL, Han T, Fuscoe JC, Lee T, Herman EH, et al. Early transcriptional changes in cardiac mitochondria during chronic doxorubicin exposure and mitigation by dexrazoxane in mice. Toxicol Appl Pharmacol. 2016;295:68–84. https://doi.org/10.1016/j.taap.2016.02.003.CrossRefPubMed

73.

Pichot CS, Hartig SM, Xia L, Arvanitis C, Monisvais D, Lee FY, et al. Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. Br J Cancer. 2009;101(1):38–47. https://doi.org/10.1038/sj.bjc.6605101.CrossRefPubMedPubMedCentral

74.

Secord AA, Teoh D, Jia J, Nixon AB, Grace L, Adams DJ, et al. Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression. Int J Gynecol Cancer. 2014;24(2):218–25. https://doi.org/10.1097/IGC.0000000000000056.CrossRefPubMedPubMedCentral

75.

Aggerholm-Pedersen N, Demuth C, Safwat A, Meldgaard P, Kassem M, Sandahl SB. Dasatinib and doxorubicin treatment of sarcoma initiating cells: a possible new treatment strategy. Stem Cells Int. 2016;2016:9601493.CrossRef

76.

Yu M, Zou Q, Wu X, Han G, Tong X. Connexin 32 affects doxorubicin resistance in hepatocellular carcinoma cells mediated by Src/FAK signaling pathway. Biomed Pharmacother. 2017;95:1844–52. https://doi.org/10.1016/j.biopha.2017.09.065.CrossRefPubMed

77.

Kohrman AQ, Matus DQ. Divide or conquer: cell cycle regulation of invasive behavior. Trends Cell Biol. 2017;27(1):12–25. https://doi.org/10.1016/j.tcb.2016.08.003.CrossRefPubMed

78.

Stravopodis DJ, Karkoulis PK, Konstantakou EG, Melachroinou S, Lampidonis AD, Anastasiou D, et al. Grade-dependent effects on cell cycle progression and apoptosis in response to doxorubicin in human bladder cancer cell lines. Int J Oncol. 2009;34(1):137–60.PubMed

79.

Lupertz R, Watjen W, Kahl R, Chovolou Y. Dose- and time-dependent effects of doxorubicin on cytotoxicity, cell cycle and apoptotic cell death in human colon cancer cells. Toxicology. 2010;271(3):115–21. https://doi.org/10.1016/j.tox.2010.03.012.CrossRefPubMed

80.

Kawauchi T. Cell adhesion and its endocytic regulation in cell migration during neural development and cancer metastasis. Int J Mol Sci. 2012;13(4):4564–90. https://doi.org/10.3390/ijms13044564.CrossRefPubMedPubMedCentral

81.

Ren F, Tang R, Zhang X, Madushi WM, Luo D, Dang Y, et al. Overexpression of MMP family members functions as prognostic biomarker for breast cancer patients: a systematic review and meta-analysis. PLoS One. 2015;10(8):e0135544. https://doi.org/10.1371/journal.pone.0135544.CrossRefPubMedPubMedCentral

82.

Morgia G, Falsaperla M, Malaponte G, Madonia M, Indelicato M, Travali S, et al. Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Urol Res. 2005;33(1):44–50. https://doi.org/10.1007/s00240-004-0440-8.CrossRefPubMed

83.

Winer A, Adams S, Mignatti P. Matrix metalloproteinase inhibitors in cancer therapy: turning past failures into future successes. Mol Cancer Ther. 2018;17(6):1147–55. https://doi.org/10.1158/1535-7163.MCT-17-0646.CrossRefPubMedPubMedCentral

84.

Spallarossa P, Altieri P, Garibaldi S, Ghigliotti G, Barisione C, Manca V, et al. Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: the role of MAP kinases and NAD(P)H oxidase. Cardiovasc Res. 2006;69(3):736–45. https://doi.org/10.1016/j.cardiores.2005.08.009.CrossRefPubMed

85.

Chan BYH, Roczkowsky A, Moser N, Poirier M, Hughes BG, Ilarraza R, et al. Doxorubicin induces de novo expression of N-terminal-truncated matrix metalloproteinase-2 in cardiac myocytes. Can J Physiol Pharmacol. 2018;96(12):1238–45. https://doi.org/10.1139/cjpp-2018-0275.CrossRefPubMed

86.

Poincloux R, Lizarraga F, Chavrier P. Matrix invasion by tumour cells: a focus on MT1-MMP trafficking to invadopodia. J Cell Sci. 2009;122(Pt 17):3015–24. https://doi.org/10.1242/jcs.034561.CrossRefPubMed

87.

Marechal A, Zou L. DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb Perspect Biol. 2013;5(9):a012716.CrossRef

88.

Xu X, Wang H, Liu S, Xing C, Liu Y. Aodengqimuge, et al. TP53-dependent autophagy links the ATR-CHEK1 axis activation to proinflammatory VEGFA production in human bronchial epithelial cells exposed to fine particulate matter (PM2.5). Autophagy. 2016;12(10):1832–48. https://doi.org/10.1080/15548627.2016.1204496.CrossRefPubMedPubMedCentral

89.

Fukumoto Y, Morii M, Miura T, Kubota S, Ishibashi K, Honda T, et al. Src family kinases promote silencing of ATR-Chk1 signaling in termination of DNA damage checkpoint. J Biol Chem. 2014;289(18):12313–29. https://doi.org/10.1074/jbc.M113.533752.CrossRefPubMedPubMedCentral

90.

Polonio-Vallon T, Kirkpatrick J, Krijgsveld J, Hofmann TG. Src kinase modulates the apoptotic p53 pathway by altering HIPK2 localization. Cell Cycle. 2014;13(1):115–25. https://doi.org/10.4161/cc.26857.CrossRefPubMed

91.

Jain RK, Martin JD, Stylianopoulos T. The role of mechanical forces in tumor growth and therapy. Annu Rev Biomed Eng. 2014;16(1):321–46. https://doi.org/10.1146/annurev-bioeng-071813-105259.CrossRefPubMedPubMedCentral

92.

Viallard C, Larrivee B. Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis. 2017;20(4):409–26. https://doi.org/10.1007/s10456-017-9562-9.CrossRefPubMed

Title: Sublethal doxorubicin promotes migration and invasion of breast cancer cells: role of Src Family non-receptor tyrosine kinases
Authors: Samia Mohammed
Achraf A. Shamseddine
Benjamin Newcomb
Ronald S. Chavez
Tyler D. Panzner
Allen H. Lee
Daniel Canals
Chioma M. Okeoma
Christopher J. Clarke
Yusuf A. Hannun
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Breast Cancer
Breast Cancer
Dasatinib
Published in: Breast Cancer Research / Issue 1/2021
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/s13058-021-01452-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Impact of post-diagnosis weight change on survival outcomes in Black and White breast cancer patients

Neighborhood disadvantage and individual-level life stressors in relation to breast cancer incidence in US Black women

TAZ maintains telomere length in TNBC cells by mediating Rad51C expression

Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use

Molecular analyses of triple-negative breast cancer in the young and elderly

Identification of MFGE8 and KLK5/7 as mediators of breast tumorigenesis and resistance to COX-2 inhibition

Keynote webinar | Spotlight on antibody–drug conjugates in cancer